ArticleJournal of circulating biomarkers
Circulating miRNAs (135a-5p, 646 AND 1271-5P) in Breast Cancer Diagnosis and Staging: Integrative Network and Functional Analysis.
Article in Journal of circulating biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer (BC) remains a leading cause of cancer-related mortality among women worldwide. Despite advances in molecular diagnostics, reliable non-invasive biomarkers for early detection and disease staging remain limited. Circulating microRNAs (miRNAs) are promising epigenetic regulators involved in tumor development and progression. Methods: Determination of plasma miRNA (1271-5p, miR-646, and miR-135a-5p) differential expression profiles in an Egyptian cohort comprising 111 BC patients (stages 0-IV), 25 benign breast disease cases, and 24 healthy controls. Their diagnostic and stage-specific performance was assessed alongside integrative analyses of predicted and validated biological targets with network construction. Results: miR-1271-5p was downregulated in benign tumors but overexpressed across all BC stages. miR-646 was generally downregulated, with a notable increase in stage III, whereas miR-135a-5p was elevated in benign and early-stage disease before declining in metastatic stage IV. ROC analyses demonstrated strong discriminatory performance, with miR-1271-5p distinguishing early-stage BC from controls and benign lesions, miR-646 separating benign/early malignant cases from controls, and miR-135a-5p identifying metastatic disease. Combined miRNA panels improved discrimination between malignant and non-malignant samples and between early and advanced stages. Integrative analyses identified putative regulation of ZEB1, CCND2, FOXN3, and RUNX2, while TP53TG1, ZFAS1, XIST, and MALAT1 emerged as potential interaction hubs. Functional enrichment suggested involvement in AMPK, FOXO, SUMOylation, TP53-mediated, and immune-related pathways. Conclusions: Circulating miR-1271-5p, miR-646, and miR-135a-5p, individually and in combination, show promise as non-invasive diagnostic and stage-specific biomarkers for BC. Integrative network analyses provide insight into their putative roles in BC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.